HIFs (Hypoxia-inducible factors) are transcription factors that react to variations in the amount of oxygen available to cells, more specifically, to reductions in oxygen, or hypoxia. The effects of hypoxia, a condition of low oxygen concentration, on the cell are mediated by the HIF signaling cascade. Oftentimes, hypoxia prevents cells from differentiating. However, hypoxia encourages the growth of blood vessels and is crucial for the development of a vascular system in both cancer tumors and embryos.Additionally, the hypoxia in wounds encourages keratinocyte migration and epithelium repair. HIFs are essential to development in general. HIF-1 gene deletion in mammals causes perinatal death. It has been demonstrated that HIF-1 is essential for chondrocyte survival and enables the cells to adapt to low oxygen environments in the growth plates of bones. Human metabolism is controlled in large part by HIF. A number of medications that function as selective HIF prolyl hydroxylase inhibitors have recently been created.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
![]() |
V89016 | DS-1093a | DS-1093a is a highly active HIF-PHD inhibitor with an EC50 value of 0.49 μM for EPO production in Hep3B cells. | |
![]() |
V87495 | DS44470011 | 1192586-35-8 | DS44470011 is an inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHD). |
![]() |
V87496 | DYB-03 | 2982792-85-6 | DYB-03 is an orally active HIF-1α/EZH2 inhibitor. |
![]() |
V3443 | EL102 | 1233948-61-2 | EL102,a novel toluidine sulphonamide, is a novel inhibitor of HIF1α (hypoxia inducible factor) and can also potently inhibit tubulin polymerisation and decreased microtubule stability. |
![]() |
V87507 | EZN-2968 | 1098309-50-2 | EZN-2968 is an antisense oligonucleotide that specifically binds to and inhibits the expression of HIF-1α mRNA. |
![]() |
V87505 | EZN-2968 sodium | EZN-2968 sodium is an antisense oligonucleotide that specifically binds to and inhibits the expression of HIF-1α mRNA. | |
![]() |
V79383 | FAM-DEALA-Hyp-YIPMDDDFQLRSF-NH2 | FAM-DEALA-Hyp-YIPMDDDFQLRSF-NH2 is a 5-FAM-labeled HIF-1α peptide and a substrate of VHL. | |
![]() |
V79782 | HIF-1 alpha (556-574) (TFA) | HIF-1 alpha (556-574) TFA is a short 19 amino acid (AA) peptide of hypoxia-inducible factor-1 (HIF-1). | |
![]() |
V51612 | HIF-1 inhibitor-4 | 333357-56-5 | HIF-1 inhibitor-4 is a HIF-1 inhibitor (IC50= 560 nM). |
![]() |
V78503 | HIF-1 inhibitor-5 | HIF-1 inhibitor-5 (Compound 16e) is a potent HIF-1 inhibitor (antagonist) with IC50 of 2.38 μM. | |
![]() |
V51614 | HIF-1/2α-IN-1 | 2827693-99-0 | HIF-1/2α-IN-1 is a HIF-2α receptor that is transcriptionally active. |
![]() |
V76933 | HIF-1α-IN-2 hydrochloride | HIF-1α-IN-2 HCl is a potent HIF-1α inhibitor (antagonist) with anticancer effects, with IC50s of 28 nM and 15 nM in MDA-MB-231 and MiaPaCa-2 cells, respectively. | |
![]() |
V51616 | HIF-1α-IN-4 | 2826221-23-0 | HIF-1α-IN-4 is a form of HIF-1α with IC50 of 24 nM in HEK293T cells. |
![]() |
V51613 | HIF-1α-IN-5 | 2826221-10-5 | HIF-1α-IN-5 is a HIF-1α reagent with IC50 of 24 nM in HEK293T cells. |
![]() |
V79721 | HIF-1α-IN-6 | HIF-1α-IN-6 (compound 3s) is a HIF-1α inhibitor (antagonist) with IC50s of 0.6 and 53.3 nM observed in MiaPaCa-2 and MDA-MB-231 cells. | |
![]() |
V87493 | HIF-1α-IN-7 | 3026685-76-4 | HIF-1α-IN-7 (Compound D13) is a potent HIF-1α inhibitor. |
![]() |
V51618 | HIF-2α agonist 2 | 2750141-15-0 | HIF-2α Agonist 2 (Compound 10) is a HIF-2α agonist/activator with EC50 of 1.68 μM at a dose of 20 μM. |
![]() |
V83427 | HIF-2α agonist 3 | ||
![]() |
V87492 | HIF-2α-IN-10 | 3034532-74-3 | HIF-2α-IN-10 (17) is a HIF-2α inhibitor with an IC50 value of 0.05 μM. |
![]() |
V87487 | HIF-2α-IN-11 | 3034589-50-6 | HIF-2α-IN-11 (1) is a HIF-2α inhibitor with IC50 of 59.2 nM. |